These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 33687432

  • 1. Development of luspatercept to treat ineffective erythropoiesis.
    Kubasch AS, Fenaux P, Platzbecker U.
    Blood Adv; 2021 Mar 09; 5(5):1565-1575. PubMed ID: 33687432
    [Abstract] [Full Text] [Related]

  • 2. Luspatercept in Myelodysplastic Syndromes: Who and When?
    Komrokji RS.
    Hematol Oncol Clin North Am; 2020 Apr 09; 34(2):393-400. PubMed ID: 32089218
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Luspatercept in low-risk myelodysplastic syndromes: a paradigm shift in treatment strategies.
    Molica M, Rossi M.
    Expert Opin Biol Ther; 2024 Apr 09; 24(4):233-241. PubMed ID: 38555469
    [Abstract] [Full Text] [Related]

  • 7. Luspatercept as a therapy for myelodysplastic syndromes with ring sideroblasts.
    Schulz F, Nachtkamp K, Kasprzak A, Gattermann N, Haas R, Germing U.
    Expert Rev Hematol; 2021 Jun 09; 14(6):509-516. PubMed ID: 34161752
    [Abstract] [Full Text] [Related]

  • 8. Activin Receptor II Ligand Traps and Their Therapeutic Potential in Myelodysplastic Syndromes with Ring Sideroblasts.
    Mies A, Hermine O, Platzbecker U.
    Curr Hematol Malig Rep; 2016 Dec 09; 11(6):416-424. PubMed ID: 27595736
    [Abstract] [Full Text] [Related]

  • 9. Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
    Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, Ilhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, Giai V, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.
    N Engl J Med; 2020 Jan 09; 382(2):140-151. PubMed ID: 31914241
    [Abstract] [Full Text] [Related]

  • 10. Luspatercept: A Review in Transfusion-Dependent Anaemia due to Myelodysplastic Syndromes or β-Thalassaemia.
    Kang C, Syed YY.
    Drugs; 2021 Jun 09; 81(8):945-952. PubMed ID: 33970460
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Myelodysplastic syndromes with ring sideroblasts.
    Bruzzese A, Vigna E, Martino EA, Mendicino F, Lucia E, Olivito V, Bova C, Barbato A, Filippelli G, Capodanno I, Neri A, Morabito F, Gentile M.
    Hematol Oncol; 2023 Oct 09; 41(4):612-620. PubMed ID: 36794650
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Novel agents for myelodysplastic syndromes.
    Xu K, Hansen E.
    J Oncol Pharm Pract; 2021 Dec 09; 27(8):1982-1992. PubMed ID: 34558354
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Ineffective erythropoiesis and its treatment.
    Cazzola M.
    Blood; 2022 Apr 21; 139(16):2460-2470. PubMed ID: 34932791
    [Abstract] [Full Text] [Related]

  • 18. The prognostic value of serum erythropoietin in patients with lower-risk myelodysplastic syndromes: a review of the literature and expert opinion.
    Park S, Kelaidi C, Meunier M, Casadevall N, Gerds AT, Platzbecker U.
    Ann Hematol; 2020 Jan 21; 99(1):7-19. PubMed ID: 31650290
    [Abstract] [Full Text] [Related]

  • 19. Luspatercept: First Approval.
    Markham A.
    Drugs; 2020 Jan 21; 80(1):85-90. PubMed ID: 31939073
    [Abstract] [Full Text] [Related]

  • 20. Bone marrow Tfr2 deletion improves the therapeutic efficacy of the activin-receptor ligand trap RAP-536 in β-thalassemic mice.
    Tanzi E, Di Modica SM, Bordini J, Olivari V, Pagani A, Furiosi V, Silvestri L, Campanella A, Nai A.
    Am J Hematol; 2024 Jul 21; 99(7):1313-1325. PubMed ID: 38629683
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.